SRX Global Invests in ARMR Sciences After ARMR-100 Shows Phase 1/2 Safety, Immune Response
SRXH•SRX Global announced a strategic equity investment in clinical-stage ARMR Sciences, developers of ARMR-100. ARMR-100’s Phase 1/2 trial generated anti-fentanyl antibodies in humans with favorable safety and will advance to protection efficacy studies later in 2026.
1. Investment Details
SRX Global executed a strategic equity investment in ARMR Sciences to support development of medical countermeasures against synthetic drugs. The partnership grants SRX an ownership stake while providing ARMR Sciences with capital to advance its lead candidate through clinical milestones.
2. ARMR-100 Phase 1/2 Results
ARMR-100, in a Phase 1/2 trial, successfully induced anti-fentanyl antibodies in healthy adults and exhibited a favorable safety profile. Trial data indicate that these antibodies can bind fentanyl and prevent its transport into the brain, targeting overdose prevention.
3. Next Steps for ARMR-100
Following safety and immunogenicity success, ARMR Sciences plans to initiate efficacy studies later in 2026 to evaluate ARMR-100’s protective capacity against fentanyl exposure. SRX Global’s investment is expected to fund these pivotal trials and support long-term development.
